UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.929

Sortiert nach

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

Cancer immunology research, 2015-09, Vol.3 (9), p.1052-1062

2015

Volltextzugriff (PDF)

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

Journal for Immunotherapy of Cancer, 2014-08, Vol.2 (1), Article 29

2014

Volltextzugriff (PDF)

Tumour-retained activated CCR7 + dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Nature communications, 2024-01, Vol.15 (1), p.682-682, Article 682

2024

Volltextzugriff (PDF)

Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients

Frontiers in immunology, 2021-03, Vol.12, p.626776-626776

2021

Volltextzugriff (PDF)

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.121-121, Article 121

2019

Volltextzugriff (PDF)

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Nature (London), 2022-06, Vol.606 (7915), p.791-796

2022

Volltextzugriff (PDF)

Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity

The Journal of immunology (1950), 2023-02, Vol.210 (4), p.496-503

2023

Volltextzugriff (PDF)

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (3), p.705-715

2014

Volltextzugriff (PDF)

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses

Oncoimmunology, 2014-06, Vol.3 (6), p.e28976-e28976

2014

Volltextzugriff (PDF)

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

Cancer research (Chicago, Ill.), 2007-04, Vol.67 (8), p.3927-3935

2007

Volltextzugriff (PDF)

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA

PloS one, 2012-05, Vol.7 (5), p.e36412

2012

Volltextzugriff (PDF)

In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue

The Journal of experimental medicine, 2022-06, Vol.219 (6)

2022

Volltextzugriff (PDF)

Targeting CD73 in the tumor microenvironment with MEDI9447

Oncoimmunology, 2016-08, Vol.5 (8), p.e1208875-e1208875

2016

Volltextzugriff (PDF)

The Human Vaccines Project: A roadmap for cancer vaccine development

Science translational medicine, 2016-04, Vol.8 (334), p.334ps9

2016

Volltextzugriff (PDF)

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy

Molecular therapy, 2017-08, Vol.25 (8), p.1917-1932

2017

Volltextzugriff (PDF)

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

Cancer immunology research, 2017-09, Vol.5 (9), p.755-766

2017

Volltextzugriff (PDF)

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

Cancer Immunology, Immunotherapy, 2015-06, Vol.64 (6), p.677-688

2015

Volltextzugriff (PDF)

Immunostimulant Patch Containing Heat-Labile Enterotoxin from Escherichia coli Enhances Immune Responses to Injected Influenza Virus Vaccine through Activation of Skin Dendritic Cells

Journal of Virology, 2003-05, Vol.77 (9), p.5218-5225

2003

Volltextzugriff (PDF)

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Cancer biology & therapy, 2024-12, Vol.25 (1), p.2296048-2296048

2024

Volltextzugriff (PDF)

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 2022-09, Vol.28 (17), p.3709-3719

2022

Volltextzugriff (PDF)

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

Expert review of vaccines, 2003-04, Vol.2 (2), p.253-267

2003

Volltextzugriff (PDF)

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

Nature communications, 2024-01, Vol.15 (1), p.683-683, Article 683

2024

Volltextzugriff (PDF)

Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer

Oncotarget, 2017-10, Vol.8 (53), p.90825-90841

2017

Volltextzugriff (PDF)

Transcutaneous Immunization Using Colonization Factor and Heat-Labile Enterotoxin Induces Correlates of Protective Immunity for Enterotoxigenic Escherichia coli

Infection and Immunity, 2002-03, Vol.70 (3), p.1056-1068

2002

Volltextzugriff (PDF)

1 – 25 von 1.929

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(780)
Mit Volltextzugriff
(1.834)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.926)
Japanisch
(117)
Französisch
(2)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(556)
Life Sciences & Biomedicine
(420)
Humans
(342)
Female
(173)
Animals
(157)
Male
(152)
Biological And Medical Sciences
(122)
Physical Sciences
(86)
Medical Sciences
(82)
Adult
(75)
Aged
(75)
Middle Aged
(73)
Mice
(70)
Science & Technology - Other Topics
(59)
Multidisciplinary Sciences
(54)
Biochemistry & Molecular Biology
(52)
Chemistry
(52)
Technology
(51)
Risk Factors
(48)
Fundamental And Applied Biological Sciences. Psychology
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

Tumour-retained activated CCR7 + dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients

Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses

Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA

In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue

Targeting CD73 in the tumor microenvironment with MEDI9447

The Human Vaccines Project: A roadmap for cancer vaccine development

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1

Immunostimulant Patch Containing Heat-Labile Enterotoxin from Escherichia coli Enhances Immune Responses to Injected Influenza Virus Vaccine through Activation of Skin Dendritic Cells

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity

Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer

Transcutaneous Immunization Using Colonization Factor and Heat-Labile Enterotoxin Induces Correlates of Protective Immunity for Enterotoxigenic Escherichia coli

Suchergebnisse filtern